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MTH1 Inhibitors for the Treatment of
Psoriasis
Cecilia Bivik Eding1,5, Ines Köhler1,5, Deepti Verma1, Florence Sjögren1, Claudia Bamberg2,
Stella Karsten3, Therese Pham3, Martin Scobie3, Thomas Helleday3,4, Ulrika Warpman Berglund3 and
Charlotta Enerbäck1
Inflammatory diseases, including psoriasis, are characterized by changes in redox regulation. The MTH1 pre-
vents the incorporation of oxidized nucleotides during DNA replication. Using MTH1 small-molecule in-
hibitors, we found induced apoptosis through 8-oxodeoxyguanosine triphosphate accumulation and DNA
double-strand breaks after oxidative stress in normal and malignant keratinocytes. In psoriasis, we detected
increased MTH1 expression in lesional skin and PBMCs compared with that in the controls. Using the imi-
quimod psoriasis mouse model, we found that MTH1 inhibition diminished psoriatic histological character-
istics and normalized the levels of neutrophils and T cells in the skin and skin-draining lymph nodes. The
inhibition abolished the expression of T helper type 17‒associated cytokines in the skin, which was in line with
decreased levels of IL-17eproducing gd T cells in lymph nodes. In human keratinocytes, MTH1 inhibition
prevented the upregulation of IL-17‒downstream genes, which was independent of ROS-induced apoptosis. In
conclusion, our data support MTH1 inhibition using small molecules suitable for topical application as a
promising therapeutic approach to psoriasis.
Journal of Investigative Dermatology (2021) -, -e-; doi:10.1016/j.jid.2021.01.026
INTRODUCTION
ROS are produced during normal cellular metabolism and
may damage biological macromolecules such as lipids,
proteins, and DNA (Valko et al., 2007). To counteract the
damaging effects of increased ROS production, cells upre-
gulate antioxidant defense mechanisms, including the human
MTH1. MTH1 prevents oxidized nucleotide triphosphates,
such as 8-oxodeoxyguanosine triphosphate (8-oxo-dGTP)
and 2-hydroxy-2-deoxyadenosine triphosphate (2-OH-dATP),
from being incorporated into genomic DNA (Sakumi et al.,
1993). This in turn prevents genomic instability, DNA dam-
age, and cell death.
MTH1 expression is induced in cancer cell lines and in a
wide range of solid tumors, including breast (Zhang et al.,
2017), lung (Fujishita et al., 2017), and colorectal (Koketsu
et al., 2004) cancers as a result of increased oxidative
pressure by oncogenic stimulation (Liou and Storz, 2010).
Moreover, in a variety of cancer types, a significant correla-
tion between MTH1 expression and tumor progression has
been observed. For normal cells, MTH1 activity is dispens-
able (Tsuzuki et al., 2001).
Because MTH1 was identified by the Helleday Laboratory
as a potential cancer therapeutic target (Gad et al., 2014), a
large number of potent small-molecule inhibitors have been
developed through extended pharmacological and
biochemical analysis (Gad et al., 2014). MTH1 inhibition
effectively and selectively induces cell death in cancer cells
by causing a mitotic arrest and the introduction of toxic
oxidized nucleotides into genomic DNA (Gad et al., 20191,
2014). The use of MTH1 inhibitor (MTH1i) in cancer treat-
ment is currently being evaluated in phase I clinical trials in
metastasized solid tumors and hematological cancers.
However, whereas MTH1is are a promising treatment, some
MTH1is have failed to inhibit cell proliferation through the
incorporation of 8-oxo-dGTP into DNA, possibly owing to
clinical heterogeneity in cancer tissues and resistance
mechanisms (Gad et al., 2014; Warpman Berglund et al.,
2016).
Despite the link between altered redox regulation, altered
repair responses and DNA damage, and various inflamma-
tory diseases (Chatzinikolaou et al., 2014; Glennon-Alty
et al., 2018), the potential of MTH1 inhibition in inflamma-
tory conditions has not yet been evaluated.
It has been suggested that increased levels of ROS
contribute to the pathogenesis of psoriasis, a chronic,
immune-mediated inflammatory skin disease (Cannavò et al.,
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2019; Harden et al., 2015). Although cell control is main-
tained in psoriasis and the disease is strictly benign, it shares
several features with cancer, such as the combination of
abnormal differentiation, hyperproliferation, and angiogen-
esis. This intense cellular activity in the psoriatic skin leads to
a local redox imbalance. Furthermore, a systemic redox
imbalance in patients with psoriasis has been suggested by
significantly increased levels of oxidative stress markers (e.g.,
malondialdehyde, lipid hydroperoxides, and nitric oxide),
reduced levels of antioxidants (e.g., thiols), and a reduction in
the activity of antioxidant enzymes (e.g., superoxide dis-
mutase and catalase) (Cannavò et al., 2019; Lin and Huang,
2016; Wagener et al., 2013; Zhang et al., 2019).
In this study, we evaluate an innovative treatment modality
for psoriasis that involves the targeting of redox imbalance.
Using first-in-class inhibitors against MTH1 (Gad et al., 2014;
Warpman Berglund et al., 2016), we demonstrate the proof of
concept of oxidative DNA repair inhibitors in a preclinical
psoriasis mouse model.
RESULTS
The sensitivity to MTH1 inhibition in keratinocytes
correlates with ROS levels
The cell death‒inducing potential of five different MTH1is
was evaluated in normal human epidermal keratinocytes,
neonatal (HEKn) cells (Cascade Biologics, Portland, OR); in
precancerous dysplastic oral keratinocyte (DOK) cell line
(Sigma-Aldrich, St. Louis, MO); and in the squamous cell
carcinoma cell line, A431 (Sigma-Aldrich). The cells were
cultured in the presence of 0.01e10 mM MTH1i for 72 hours,
and the viability was measured using an MTT viability assay
(Figure 1a and b). All the five inhibitors induced a strikingly
similar pattern of diminished cell viability. When high con-
centrations of inhibitors were used, the A431 cells demon-
strated a significantly lower viability than seen in HEKn. The
DOK cells demonstrated an intermediate level of survival.
Normal adult keratinocytes (KCs) and KCs isolated from skin
biopsy samples displayed survival comparable with that of
the HEKn cells (data not shown).
To determine whether the survival rate correlated with the
level of intracellular ROS, we used 4-hydroxy-2-nonenal (4-
HNE) staining in immunocytochemistry, which reflects
ROS-induced lipid peroxidation. 4-HNE levels were mark-
edly higher in A431 cells than in HEKn cells (Figure 2a).
The incorporation of 8-oxo-dGTP into DNA, leading to
cellular apoptosis, is linked to efficient MTH1 inhibition
(Warpman Berglund et al., 2016). In line with the survival
data, MTH1 inhibition caused a more pronounced accumu-
lation of 8-oxo-dGTP in DNA in A431 cells than in HEKn
cells (Figure 2b). In addition, the expression of nuclear 53BP1
(Abcam) foci in A431 cells was increased, which confirms
that MTH1 inhibition leads to DNA double-strand breaks in
sensitive cells (Figure 2c). Using Annexin V and 7-
aminoactinomycin D (7AAD) double staining in flow
cytometry, we showed that the fraction of apoptotic cells was
markedly increased in A431 cells as compared with that in
HEKn cells (Figure 2d).
To evaluate whether increased levels of ROS increase the
sensitivity of HEKn to MTH1 inhibition, we treated HEKn
with the antioxidant inhibitor, L-buthionine sulfoximine
(Sigma-Aldrich), which raised intracellular ROS as well as 4-
HNE levels in the HEKn (Supplementary Figure S1). The
treatment led to significantly reduced viability in HEKn on
MTH1 inhibition (Figure 3e). Moreover, ROS augmented the
protein level of MTH1 in HEKn cells in a concentration-
dependent manner (Figure 2f). L-buthionine sulfoximine
treatment also resulted in an accumulation of 8-oxo-dGTP,
which was further augmented by MTH1 inhibition
(Figure 2g). These results show that the apoptosis-inducing
potential of the MTH1is in KCs is associated with the
severity of the oxidative stress.
MTH1 levels are increased in psoriatic skin and PBMC
To evaluate whether increased levels of ROS in psoriatic
lesional tissue may be reflected in elevated levels of MTH1,
we analyzed the expression of MTH1 in psoriatic skin and
PBMCs. We found an increased MTH1 mRNA expression in
whole-skin biopsies from both lesional and nonlesional
psoriatic skin compared with those from control skin
(Figure 3a). The upregulation was particularly pronounced in
the mRNA from the lesional epidermis compared with that
from the normal epidermis (Figure 3b). Furthermore, the
levels of MTH1 were increased in PBMCs from patients with
psoriasis compared with the levels of MTH1 in cells from
controls (Figure 3c). The immunohistochemical staining of
MTH1 revealed low expression in nonlesional skin and
strong albeit variable expression in the lower parts of the
lesional epidermis (Figure 3d). These data support the
assumption that targeting these proteins may be a promising
anti-inflammatory treatment.
MTH1 inhibition diminishes T helper type 17‒driven
inflammation in mice
We used the imiquimod (IMQ) mouse model to generate T
helper type 17‒driven psoriasiform inflammation in mice
(van der Fits et al., 2009). After 4 days of daily topical
application of IMQ onto the shaved back skin, the severity of
the dermatitis was evaluated. Compared with mice treated
with only IMQ, mice treated with MTH1i and IMQ (MTH1i-
IMQ) demonstrated reduced skin erythema (Figure 4a). A
histological examination of the IMQ-treated mice confirmed
acanthosis, parakeratosis, and a dermal infiltrate with dilated
vessels, which were all significantly reduced by MTH1 in-
hibition (Figure 4b). Mouse body weight did not change as a
result of MTH1 inhibition, suggesting limited severe side ef-
fects (data not shown).
The immunofluorescence staining of lesional skin
revealed that CD45þ hematopoietic cells were markedly
diminished in MTH1i-IMQ‒treated mice compared with
that in IMQ-treated mice (Figure 4c). Using the neutrophil
marker, Ly6B, we found that the CD45þ cells primarily
consisted of neutrophils, demonstrating a neutrophil influx
in response to IMQ, which was strikingly downregulated by
MTH1 inhibition (Figure 4c). The number of CD3þ cells was
similar to that in the control skin and in IMQ-treated skin
(Figure 4d), which is in line with the reported accumulation
of gd T cells beyond 4 days of IMQ treatment (Tortola et al.,
2012). There was a markedly reduced number of CD3þ cells
in the skin of MTH1i-IMQ‒treated mice, suggesting that T
cells may only be sensitive to MTH1 inhibition when
activated.
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In addition, MTH1 inhibition was found to increase the
number of oxidized nucleotides, detected with 8-oxo-dGTP
staining, in the basal layer of the epidermis in lesional skin
(Figure 4e). There was also an increased number of 53BP1
nuclear foci in the epidermal KCs in the skin of MTH1i-IMQ‒
treated skin, indicating DNA damage (Figure 4f).
We analyzed the mRNA levels of T helper type 17‒
associated cytokines in the murine skin by qPCR and found a
A431
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Figure 1. Skin cancer cell lines are more sensitive to MTH1 inhibition than normal KCs (a) Viability analyses in HEKn cells, in the A431 human squamous
carcinoma cell line, and in the DOK cell line treated with five small-molecule MTH1is (0.01e10 mM; TH1927, TH1928, TH2457, TH7686, and TH3299) for 72
hours. Statistical significances between HEKn and A431 are shown. n ¼ 3e6, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (b) Representative
photographs of the human squamous carcinoma cell line (A431) and HEKn cells showing the control cells and the cells treated with different concentrations of
MTH1i (TH1927). Bar ¼ 200 mm. DOK, dysplastic oral keratinocyte; HEKn, normal human epidermal keratinocytes, neonatal; KC, keratinocyte; MTH1i, MTH1
inhibitor.
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Figure 2. The sensitivity of the MTH1is correlates with the severity of the oxidative stress. (a) Increased ROS-induced lipid peroxidation in human squamous
carcinoma cells (A431) compared with those in HEKn. 4-HNE staining in immunocytochemistry: red, 4-HNE; blue, DAPI (nuclei). Bar ¼ 100 mm. n ¼ 3. MTH1
inhibition triggers the pronounced accumulation of (b) 8-oxo-dGTP and (c) 53BP1 induction in the human squamous carcinoma cell line (A431) compared with
that in the HEKn cells. Green, 8-oxo-dGTP; red, 53BP1; blue, DAPI (nuclei). Bar¼ 50 mm. n¼ 3. (d) Flow cytometry analysis of Annexin V and 7AAD expression
in the MTH1i (0.5 mM, TH1927)-treated A431 and HEKn. The percentage of early apoptotic cells (Annexin Vþ and 7AAD) is presented. (e) An elevated ROS
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complete abolition of Il-17a and Il-22 expression, along with
strikingly reduced levels of Tnf-a and Il-23 in MTH1i-IMQ‒
treated mice compared with that in IMQ-treated mice
(Figure 4g). The topical treatment of mice with IMQ resulted
in systemic effects on the cellular composition of the spleen,
with a shift from lymphoid to myeloid cells (van der Fits et al.,
2009). In line with this, IMQ led to spleen enlargement and
an increased spleen index (Figure 4h). This was significantly
reduced in MTH1i-IMQ‒treated mice. Using flow cytometry,
we found reduced levels of splenic CD4þ and CD8þ T cells
in IMQ-treated mice, and these levels were normalized by
MTH1 inhibition (Figure 5a). Similar results were observed in
skin-draining lymph nodes (Figure 5b). Interestingly, IMQ
dramatically increased the fraction of Ly6G/Cþ neutrophils in
lymph nodes, but this was reduced to control level by MTH1
inhibition. This result completely confirms our immunohis-
tochemical findings.
The dominant source of IL-17 in IMQ-treated mice is the
gd T cells and, to a lesser extent, the IL-17‒producing CD4þ
cells (Cai et al., 2011). Using flow cytometry, we analyzed
the fraction of IL-17eproducing gd T cells in lymph nodes
and found that it was increased by IMQ, which tended to be
prevented by MTH1 inhibition (Figure 5c). No significant
difference was observed in the IL-17‒producing CD4þ cell
subset (data not shown). These results show a profound
alleviating effect by MTH1 inhibition in IMQ-induced pso-
riasis-like inflammation.
MTH1 inhibition regulates IL-17edriven inflammation
in vitro independently of ROS
The striking downregulation of Il-17a and Il-23 in mouse skin
treated with IMQ during MTH1 inhibition prompted us to
investigate the putative direct effect of MTH1 inhibition on
the IL-17 signaling pathway in KCs. When we treated HEKn
cells with IL-17 in combination with TNF-a, the MTH1 pro-
tein expression increased (Figure 6a). Furthermore, MTH1
inhibition led to a differential mRNA expression of the IL-17
and IL-22 downstream genes, CXCL1, CXCL5, CXCL8,
S100A8, and DEFB4 (Figure 6b and Supplementary
Figure S2). The inhibitor TH1927 demonstrated the most
=
level increases the sensitivity of the HEKn to MTH1 inhibition. The cells were cultured with MTH1i (TH1927; 0.5 mM and 2.5 mM) with or without the
glutathione synthesis inhibitor, BSO (100 mM). (f) ROS increases MTH1 protein expression in HEKn. The cells were treated for 48 hours with BSO (100 mM and
200 mM). (g) ROS induces 8-oxo-dGTP accumulation in HEKn. The KCs were cultured with BSO (200 mM) and MTH1i (TH1927; 0.1 mM and 0.5 mM) for 48
hours. Bar ¼ 50 mm: green, MTH1 and 8-oxo-dGTP; blue, DAPI (nuclei), n ¼ 3. *P < 0.05, ****P < 0.0001. 4-HNE, 4-hydroxy-2-nonenal; 7ADD, 7-
Aminoactinomycin D; 8-oxo-dGTP, 8-oxodeoxyguanosine triphosphate; BSO, L-buthionine sulfoximine; HEKn, normal human epidermal keratinocyte,















































































































Figure 3. Increased MTH1 expression in psoriatic tissues. MTH1 mRNA expression analyses of (a) whole-skin biopsies (n ¼ 5e8), (b) epidermis (n ¼ 5e6) from
psoriatic skin (Pso inv, Pso uninv) and control skin, and (c) PBMCs (n ¼ 13) from patients and controls. *P < 0.05, **P < 0.01, ***P < 0.001. (d)
Immunohistochemical MTH1 staining of psoriatic and control skin. Bar ¼ 50 mm; red, MTH1; blue, DAPI (nuclei); n ¼ 6e7. ns, nonsignificant; Pso inv, psoriatic
skin involved; Pso uninv, psoriatic skin uninvolved.
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Figure 4. MTH1 inhibition reduces inflammation and increases oxidative damage in IMQ-treated mice. Aldara cream (IMQ) was applied to the shaved backs of
mice (C57B6/J) on 4 consecutive days. The mice received a subcutaneous injection (30 mg/kg) of the MTH1i, TH1827, every other day for 5 days (days 1, 3, and
5). n ¼ 6. (a) Mice treated with IMQ developed a psoriasis-like skin inflammation with erythema, scaling, and thickening. (b) Mice skin stained with H&E. Bar ¼
100 mm. Immunofluorescence staining (red) of CD45þ, (c) Ly6Bþ, and (d) CD3þ cells in murine skin. Nuclear counterstaining with DAPI (blue). Bar ¼ 100 mm.
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pronounced decrease in the expression of the chemokines
CXCL1, CXCL5, and CXCL8 and an increase in the expres-
sion of DEFB4 and S100A8. The decrease in CXCL1 expres-
sion in response to MTH1 inhibition was confirmed at the
protein level using ELISA (Figure 6c). Interestingly, these re-
sults could not be attributed to the reduced survival of
cytokine-treated cells because we did not detect higher
sensitivity to MTH1 inhibition in the cytokine-treated cells
(Supplementary Figure S3a). Using Annexin and 7AAD
double staining in flow cytometry, the fraction of apoptotic
cells in response to cytokine treatment was unchanged
(Supplementary Figure S3b). In agreement with these find-
ings, we did not find any increase in ROS-induced damage
(4-HNE levels) in IL-17etreated cells (data not shown). Our
data suggest that MTH1 inhibition leads to a direct effect on
the IL-17 signaling pathway in KCs, which is not a conse-
quence of ROS-induced cell death.
DISCUSSION
Ongoing ROS production is believed to play an essential role
in maintaining chronic inflammation (Chatzinikolaou et al.,
2014; Smallwood et al., 2018; Wagener et al., 2013). The
activities of infiltrating leukocytes, neutrophils, and macro-
phages in inflamed tissues result in the enhanced generation
of pro-oxidant molecules (Glennon-Alty et al., 2018).
Increased protein oxidation and oxidative stress markers have
been reported in the lesional skin of patients with psoriasis
(Bacchetti et al., 2013; Lee et al., 2017), and a disturbance in
the antioxidant defense system has been suggested by
increased plasma levels of superoxide dismutase and catalase
(Cannavò et al., 2019; Zhang et al., 2019).
In this study, we have evaluated a treatment modality for
psoriasis that involves the inhibition of MTH1, resulting in a
lack of protection from oxidative damage. We showed that
precancerous and skin cancer cell lines were significantly
more sensitive to MTH1 inhibition than normal KCs. The
apoptosis-inducing potential of MTH1is in KCs correlated
with the severity of the oxidative stress. We showed an in-
crease in MTH1 expression in the involved skin and in
PBMCs from patients with psoriasis compared with those
from the controls, suggesting a potential beneficial effect by
MTH1 inhibition.
The effects of MTH1 inhibition on T helper type 17‒driven
skin inflammation were studied in mice using the potent toll-
like receptor 7 ligand, IMQ (van der Fits et al., 2009). IMQ-
induced psoriasis is a widely used model for human psoria-
sis because it is IL-17 and/or IL-23 dependent and produces a
phenotype that strongly resembles human psoriasis. We
found that the MTH1i, TH1827, reduced psoriatic histologi-
cal characteristics and strikingly reduced the dermal infiltrate
of neutrophils in IMQ-treated mice, which was also observed
in mice lymph nodes. Furthermore, the inhibition of MTH1
=
MTH1 inhibition triggered the nuclear accumulation of (e) 8-oxo-dGTP and (f) 53BP1 in the epidermis of IMQ-treated skin. Nuclear counterstaining with DAPI.
Bar ¼ 50 mm (8-oxo-dGTP) and 25 mm (53BP1). (g) Gene expression of the Il-17a, Il-22, Il-23, and Tnf-a cytokines in murine skin after MTH1i-IMQ treatment.
n ¼ 3, *P < 0.05, **P < 0.01. (h) Spleen index (spleen weight per body weight). n ¼ 3‒6, **P < 0.01. 8-oxo-dGTP, 8-oxodeoxyguanosine triphosphate; IMQ,
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Figure 5. Flow cytometry analyses of
mice spleen and skin-draining lymph
nodes. Flow cytometry analyses of
CD19-, CD4-, CD8-, NK1.1-,
Ly6G/C-, and CD11c-expressing cells
in mice (a) spleen and (b) skin-
draining lymph nodes and (c) gd T
cells and IL-17‒expressing gd T cells
in mice lymph nodes. n ¼ 3‒6,
*P > 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 compared with
control. IMQ, imiquimod; prod,
producing.
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almost abolished the expression of T helper type 17‒associ-
ated cytokines in mouse skin and led to a reduction in the
fraction of IL-17eproducing gd T cells in lymph nodes.
MTH1i-treated mice also exhibited reduced splenomegaly in
response to IMQ, suggesting an effect on systemic inflam-
mation. The MTH1 inhibition led to an accumulation of
oxidized nucleotides and an increased expression of 53BP1
in the nuclei of epidermal cells, indicating DNA damage.
Interestingly, we have found that IL-17 increases MTH1
expression and that MTH1 inhibitors prevent the upregu-
lation of IL-17edownstream genes in cultured human KCs.
The epidermal recovery after MTH1 inhibition in the
mouse model may therefore be a consequence of a direct
effect on the KCs rather than solely a secondary effect to
the strong reduction in the inflammatory infiltrate. The
effect on IL-17‒downstream genes was not associated with
increased ROS levels and apoptosis, suggesting the pres-
ence of an IL-17‒modulating effect of MTH1 inhibition,
which increases the relevance to the treatment of psoriasis.
Moreover, the MTH1-independent effects of the inhibitor
cannot be excluded.
In several of the commonly used therapies for psoriasis,
such as UV therapy and low-dose methotrexate, the
apoptosis of KCs and dermal leukocytes in response to ROS is
an important part of their mode of action (Elango et al., 2014;
Gu et al., 2015; Vieyra-Garcia and Wolf, 2018). Moreover,
TNF-a was shown to induce ROS in KCs (Young et al., 2008),
and treatment with the TNF-a inhibitor, etanercept, led to the
reduction of lipid peroxidation and an increase in antioxidant
capacity (Bacchetti et al., 2013). The inhibition of MTH1,
which normally protects cells from oxidative damage,
thereby leading to cellular apoptosis, is therefore an inter-
esting modality of treatment for psoriasis.
In conclusion, we have successfully found support for the
inhibition of MTH1, implicated in the oxidative stress
response, as a treatment modality for psoriasis using small-
molecule inhibitors that are suitable for topical application.




































































































































Figure 6. MTH1 regulates IL-17‒downstream genes. (a) Immunocytochemical staining of MTH1 on HEKn treated with a combination of IL-17 and TNF-a.
Nuclear counterstaining with DAPI. Bar ¼ 50 mm. (b) Gene expression analyses of CXCL1, CXCL5, CXCL8, BD2, and S100A8 in HEKn pretreated with IL-17A
and TNF-a 24 hours before the MTH1i, TH1927 (2.5 mM), was added for 48 hours. n ¼ 3. (c) ELISA analysis of CXCL1 protein levels in conditioned media from
HEKn after IL-17A and TNF-a and TH1927 treatment. The protein levels are correlated with cell amount. n ¼ 3. HEKn, normal human epidermal keratinocyte,
neonatal; MTH1i, MTH1 inhibitor; w/o, without.
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The MTH1is were provided by the Helleday Laboratory, Karolinska
Institute, Stockholm, Sweden (WO2014084778).
Isolation of epidermal KCs from human skin biopsies
Punch biopsies (4 mm) from involved and uninvolved psoriatic skin
were obtained from patients at the Department of Dermatology at
Linköping University Hospital (Sweden), which was approved by the
Institutional Review Board at Linköping University (Sweden). All
participants had given their written informed consent, and the pa-
tients were examined by a dermatologist and were not receiving any
systemic treatment.
The biopsies were incubated with 3.8% ammonium thiocyanate
for 30 minutes at room temperature or with dispase (2 mg/ml, Roche
Diagnostics, Mannheim, Germany) at 4 C for 18 hours. For qPCR,
the epidermis was placed in RLT plus buffer (for further details, see
the section on qPCR given later). For KC cell culture, the epidermis
was placed in 0.05% trypsin with mechanical disruption for 30
minutes at 37 C and filtered through a 40-mm nylon cell strainer.
Cells for culture and culture conditions
HEKn cells, the human squamous carcinoma cell line (A431), and
the dysplastic oral KC cell line, DOK were cultured according to the
recommended procedures. For detailed culture conditions for the
cell lines and for KCs isolated from skin biopsies, see the
Supplementary Materials and Methods.
Cells were treated with IL-17A (200 ng/ml) in combination with
TNF-a (10 ng/ml) (both from R&D Systems, Minneapolis, MN) for
24e48 hours. The following MTH1is were used at concentrations of
0.01e10 mM: TH1927, TH1928, TH2457, TH7686, and TH3299.
When indicated, cells were pretreated with cytokines 24 hours
before treatment with the MTH1i. The inhibitor of glutathione syn-
thesis, L-buthionine sulfoximine (Sigma-Aldrich), was used at con-
centrations of 50e200 mM.
RNA extraction, cDNA synthesis, and qPCR
Skin harvested from humans and mice was snap frozen in liquid
nitrogen and homogenized. RNA was then extracted with the
RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. Cells and epidermis
layers were lysed in RLT plus buffer and extracted using the RNeasy
Mini Kit (Qiagen).
The Maxima First Strand cDNA Synthesis Kit (Thermo Fisher
Scientific, Vilnius, Lithuania) was used for cDNA synthesis. Gene
expression was evaluated by qPCR and was performed on a Real-
Time 7500 HT System (Applied Biosystems, Foster City, CA) using
the TaqMan Fast Advanced Master Mix and predesigned TaqMan
Gene expression assays or SYBR green (Applied Biosystems)
(Supplementary Materials and Methods). Measurements were per-
formed in triplicate, and expression data were normalized to RPLP0
endogenous control using the comparative Ct (2-DDCt) method.
Cell viability assay
Cell survival was evaluated after 72 hours of MTH1i treatment using
the PrestoBlue Cell Viability Reagent (Life Technologies, Carlsbad,
CA) according to the manufacturer’s instructions. The optical density
readings were measured at 570 and/or 600 nm in a VersaMax
Microplate Reader (Molecular Devices, Sunnyvale, CA). All samples
were run in triplicate.
Immunofluorescence and immunohistochemistry
Cells were fixed in 4% formaldehyde and permeabilized with 0.1%
saponin. They were stained with primary MTH1 (Novus Biologicals,
Littleton, CO), 53BP1, or 4-HNE antibodies (both from Abcam,
Cambridge, UK) overnight at 4 C, followed by incubation with
secondary Alexa Fluor 488 or 555 conjugated antibody (Molecular
Probes, Eugene, OR) for 1 hour at room temperature. For the staining
of 8-oxo-dGTP, Alexa 488‒conjugated avidin (Life Technologies)
was used (Struthers et al., 1998).
For immunohistochemistry, human and mouse skin punch bi-
opsies were fixed and paraffin embedded. The 5 mm sections were
deparaffinized in Histolab Clear (Histolab Products, Gothenburg,
Sweden) and rehydrated in ethanol. Heat-induced antigen retrieval
was performed in a citrate antigen retrieval buffer (pH ¼ 6, Dako,
Glostrup, Denmark). After blocking in 5% BSA for 45 minutes at
room temperature, the sections were either stained with H&E (His-
tolab Products) or incubated with primary antibody (Supplementary
Materials and Methods) overnight at 4 C, followed by 1 hour of
incubation with Alexa Fluor 555 or 488-conjugated secondary plus
antibody. For staining of 8-oxo-dGTP, Alexa 488‒conjugated avidin
was used. The nuclei were counterstained with DAPI.
Staining was analyzed in an AxioVert.A1 Microscope (Zeiss,
Oberkochen, Germany). Negative controls were obtained by omit-
ting the primary antibody, and they displayed no staining.
ELISA
CXCL1 protein levels in conditioned medium were measured using
the human CXCL1/GROa Quantikine ELISA Immunoassay Kit (R&D
Systems) according to the manufacturer’s instructions and were
measured in duplicate. The protein levels were correlated with cell
amount, and the absorbance was measured in a VersaMax Micro-
plate Reader.
Mouse experiment
C57B6/J female mice were obtained from the Janvier Laboratory
(Janvier, Le Genest-St-Isle, France). Animal procedures were per-
formed with the consent of the Institutional Animal Care and Use
Committee at Linköping University. The mice received a daily
topical application of 62.5 mg Aldara cream (5% IMQ, Meda AB,
Solna, Sweden) on a shaved back region (3  2 cm) for 4 consec-
utive days. The mice received a subcutaneous injection (30 mg/kg)
of the MTH1i, TH1827, every other day for 5 days (days 1, 3, and 5).
The mice were killed on day 5 after 1 hour of the last inhibitor in-
jection. Control mice were sham treated with Vaseline cream (ACO,
Kista, Sweden). Skin, spleens, and lymph nodes were collected.
Flow cytometry
Cells from the spleen and lymph node were prepared. The broad
immunophenotyping panel used is described in the Supplementary
Materials and Methods. Live and/or dead estimation was based on
7AAD or Fixable Viability Stain 510 (BD Biosciences, San Jose, CA)
staining. A total of 3e500,000 viable cells in the forward scatter/live
gate were collected on FACS ARIA III instrument and analyzed using
Kalzua, version 2.1 (Beckman Coulter, Bromma, Sweden), using
fluorescence minus one gate. The gating strategy is shown in
Supplementary Figure S4.
Cells from lymph nodes were stimulated for 4 hours with 50 ng/ml
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) and 1 mg/ml
ionomycin (Sigma-Aldrich) in the presence of brefeldin A (BD
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Biosciences). The surface staining panel is described in the
Supplementary Materials and Methods. Cells were then fixed and
permeabilized using BD Cytofix/Cytoperm Fixation/Permeabiliza-
tion Solution Kit (Gray et al., 2013) according to the manufacturer’s
instructions and were stained intracellularly with antimouse IL-17A-
PE (BD Biosciences). The specificity of intracellular staining was
ensured by blocking with unlabeled mAb of the same clone. A total
of 50e100,000 viable single CD3þ cells were collected for further
analysis by Kalzua, version 2.1 (Supplementary Figure S4).
Apoptosis was analyzed using PE-Annexin V Apoptosis Detection
Kit I (BD Biosciences). The dead and damaged cells were detected
using 7AAD. The cells were acquired on a Gallios flow cytometer
and analyzed using Kaluza software. The Annexin V 7AAD cell
population was considered viable.
Statistics
Differences between groups were analyzed using Student’s t-test in
all experiments apart from those analyzing viability in different cell
types exposed to MTH1is, where one-way ANOVA followed by
Sidak’s multiple comparison post-test were performed. P  0.05 was
considered significant. Statistical analyses were performed using
GraphPad Prism, version 8.0.1 (GraphPad Software, San Diego, CA).
The data are presented as the mean  SEM.
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SUPPLEMENTARY MATERIALS AND METHODS
Cells for culture and culture conditions
Normal human epidermal neonatal keratinocytes, neonatal
cells were cultured in a complete EpiLife medium supple-
mented with 1% EpiLife defined growth supplement and
calcium chloride (0.06 mM; all from Cascade Biologics,
Portland, OR). The human squamous carcinoma cell line,
A431 (Sigma-Aldrich, St. Louis, MO), was grown in MEM,
supplemented with 10% fetal bovine serum (Gibco, Gai-
thersburg, MD), 2 mM L-glutamine (Gibco), and 1% MEM
nonessential amino acids (Sigma-Aldrich). The dysplastic oral
KC cell line (Sigma-Aldrich) was cultured in DMEM supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine, and
5 mg/ml hydrocortisone (Sigma-Aldrich). KCs isolated from
skin biopsies were cultured in KC serum‒free medium with L-
glutamine supplemented with 25 mg/ml bovine pituitary
extract and 1 ng/ml EGF (Gibco). All the media also con-
tained 1% amphotericin B (Gibco) and 1% penicillin and
streptomycin (Lonza, Verviers, Belgium).
RNA extraction, cDNA synthesis, and qPCR
The following predesigned TaqMan Gene expression
assays (Applied Biosystems, Foster City, CA) were used:
CXCL1 (Hs00236937_m1), CXCL5 (Hs01099660_g1),
CXCL8 (Hs00174103_m1), S100A8 (Hs00374264_g1),
BD2 (Hs00175474_m1), and RPLP0 (Hs99999902_m1)
for human expression and Il-17a (Mm00439618_m1), Il-
22 (Mm01226722_g1), Il-23a (Mm00518984_m1), Tnf-a
(Mm00443258_m1), and Rplp0 (Mm00725448_s1) for
mouse expression. SYBR green (Applied Biosystems) was
used for the expression analysis of MTH1 using the
following primer sequences: MTH1: forward 50-GTGCA-
GAACCCAGGGACCAT-30 and reverse 50-GCCCACGAACT-
CAAACACGA-30 (Gad et al., 2014) and RPLP0: forward 50-
ACTGTGCCAGCCCAGAACA-30 and reverse 50-AGCCTG-
GAAAAAGGAGGTCTT-30.
Immunohistochemistry
The following primary antibodies were used: CD45 (Abcam,
Cambridge, United Kingdom), Ly6B.2 (Novus Biologicals,
Littleton, CO), CD3 (Abcam), MTH1 (Novus Biologicals), and
53BP1 (Abcam).
Flow cytometry
The broad immunophenotyping panel included antimouse
CD8-AlexaFlour700, CD11b-APC, CD11c-BrilliantViolet
421, Ly6G/C-BrilliantViolet 786, and NK1.1-PECy7 (all from
BD Biosciences, San Jose, CA), CD19-FITC (from Nordic
Biosite, Stockholm, Sweden), and anti‒CD4-PECy5.5 (eBio-
science, San Diego, CA).
For the IL-17A staining of the lymph nodes, surface staining
with antimouse CD11b-BrilliantViolet 650, CD3-PECF594,
and gd TCR-BrilliantViolet 421 (all from BD Biosciences);
anti‒CD196-BrilliantViolet 786 and anti‒CD19-FITC (Nordic
Biosite); and anti‒CD4-PECy5.5 (eBioscience) was first per-
formed. Anti-mouse IL-17AePE (BD Biosciences) was used
for intracellular staining.
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Supplementary Figure S1. Treatment with antioxidant inhibitor results in
increased ROS and lipid peroxidation in KCs. Incubation with the glutathione
synthesis inhibitor, BSO (50e200 mM), resulted in increased (a) ROS levels
(n ¼ 1) and (b) 4-HNE (n ¼ 3) immunocytochemical staining in HEKn. Red, 4-
HNE; blue, DAPI (nuclei). Bar ¼ 100 mm. 4-HNE, 4-hydroxy-2-nonenal; BSO,
L-buthionine sulfoximine; HEKn, normal human epidermal keratinocyte,
neonatal; KC, keratinocyte.
C Bivik Eding et al.
MTH1 Inhibitors for the Treatment of Psoriasis
Journal of Investigative Dermatology (2021), Volume -12.e2
a
Control IL-17 + TNF- Control IL-17 + TNF-
Control IL-17 + TNF- Control IL-17 + TNF-
Control IL-17 + TNF-
Control IL-17 + TNF-
Control IL-17 + TNF-
Control IL-17 + TNF-
Control IL-17 + TNF-


































































































































































Supplementary Figure S2. MTH1 regulates IL-17‒downstream genes. Gene expression analyses of CXCL1, CXCL5, CXCL8, BD2, and S100A8 in HEKn
pretreated with IL-17A and TNF-a 24 hours before the MTH1i (a) TH1928 (2.5 mM) or (b) TH7686 (2.5 mM) was added for 48 hours. n ¼ 3. HEKn, normal human
epidermal keratinocyte, neonatal; MTH1i, MTH1 inhibitor; w/o, without.
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Supplementary Figure S3. Cytokine treatment does not increase sensitivity
to MTH1 inhibition. HEKn were cultured with a combination of IL-17A and
TNF-a for 24 hours before MTH1i (TH3299, 2.5 mM) treatment for 48 hours.
(a) Viability was measured with a PrestoBlue viability assay. n ¼ 3. (b) Flow
cytometry analysis of Annexin V expression. n ¼ 3. HEKn, normal human
epidermal keratinocyte, neonatal; MFI, median fluorescence intensity;
MTH1i, MTH1 inhibitor.
Supplementary Figure S4. Gating strategies for flow cytometry analyses.
Gating strategies for immunophenotyping of cells from (a) lymph node and
spleen tissues, and (b) lymphocyte intracellular staining of the lymph nodes.
FSC-A, forward scatter area.
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